Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : AAV00129Z
Serotype : AAV Serotype 1 Storage : -80 ℃
Titer: Size:
| Cat. No. | AAV00129Z |
| Description | AAV serotype 1 particles contain FLPo recombinase under CAG promoter. |
| Serotype | AAV Serotype 1 |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 100 μL, 500 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Summary | Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
Many unique properties make AAV a very promising vector for human gene therapy. AAV is not associated with any known human disease and is generally not considered pathogenic. Wild-type AAV is able to integrate into host chromosomes in a site-specific manner. Recombinant AAV (rAAV) vectors can integrate into tissue culture cells at chromosome 19 if the Rep protein is provided in trans. Transduced genomes of AAV have been shown to produce long-term gene expression in a variety of tissues, including muscle, liver, brain, and retina.
Of AAV-1 to AAV-6, only AAV-1 and AAV-4 are considered simian viruses because they were isolated from non-human primates and monospecific antibodies against these viruses have not been detected in human sera. They may have advantages for human gene therapy and could replace or augment the use of AAV-2 vectors. For example, AAV-1 vectors could be used in patients who have developed anti-AAV-2 neutralizing antibodies (NABs) due to naturally acquired infection or previous treatment with AAV-2 vectors.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
I’ve been using the AAV1-CAG-FLPo for my gene therapy research, and the results have been outstanding.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.